



Company Overview

Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

European Medicines Agency validates Oasmia Pharmaceutical AB's application to add efficacy data to the approved Apealea® product information

Jan 15 2019, 2:00 AM EST

New U.S. patent related to Oasmia Pharmaceutical's nanotechnology platform XR17 has been granted

Nov 20 2018, 2:00 AM EST

Stock Overview

Symbol	OASM
Exchange	Nasdaq
Shares OS	179,309,596
Market Cap	\$240.27M
Last Price	\$1.34
52-Week Range	\$1.20 - \$5.70

06/27/2019 03:55 PM EDT

Investor Relations

Oasmia Pharmaceutical AB
Mikael Asp
Chief Executive Officer
Vallongatan 1
752 28, Uppsala
Sweden
T: +46 18 50 54 40
info@oasmia.com

Management Team

Mikael Asp

Chief Executive Officer

Joakim Lindén

Acting Chief Financial Officer

Oasmia Pharmaceutical AB

Vallongatan 1
Uppsala 752 28
Sweden

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.